{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T15:26:07Z","timestamp":1788276367133,"version":"build-2803163510"},"reference-count":23,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T00:00:00Z","timestamp":1597190400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Takeda Pharmaceutical"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Urology"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of cabozantinib, through a bridging study to METEOR, in Japanese patients with advanced renal cell carcinoma who had progressed after prior tyrosine kinase inhibitor therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This phase\u00a0II, open\u2010label, single\u2010arm study (ClinicalTrials.gov registration number: NCT03339219) included adult Japanese patients with advanced renal cell carcinoma and measurable disease who had received one or more tyrosine kinase inhibitors. Patients received cabozantinib 60\u00a0mg orally once daily while there was clinical benefit, or until unacceptable toxicity or disease progression. The primary end\u2010point was objective response rate per Response Evaluation Criteria in Solid Tumors Version 1.1. Secondary end\u2010points included clinical benefit rate (complete or partial response, or \u22658\u2010week stable disease), progression\u2010free survival, overall survival and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 35 patients enrolled, 68.6%, 22.9% and 8.6% had previously received one, two and three prior tyrosine kinase inhibitors, respectively. The median duration of cabozantinib exposure was 27.0\u00a0weeks (range 5.1\u201343.0\u00a0weeks). The objective response rate was 20.0% (90% confidence interval 9.8\u201334.3%), and the clinical benefit rate was 85.7% (95% confidence interval 69.7\u201395.2%). The 6\u2010month estimated progression\u2010free survival was 72.3% (95% confidence interval 53.3\u201384.6%); the median progression\u2010free survival and overall survival were not reached. All patients reported adverse events, which were manageable by supportive treatment or dose modification; two patients (5.7%) discontinued therapy due to adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The results showed that findings from METEOR can be extrapolated, and that cabozantinib 60\u00a0mg\/day is a viable treatment option in Japanese patients with advanced renal cell carcinoma who had progressed after prior tyrosine kinase inhibitor therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/iju.14329","type":"journal-article","created":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T02:30:52Z","timestamp":1597285852000},"page":"952-959","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Cabozantinib in advanced renal cell carcinoma: A phase\u00a0II, open\u2010label, single\u2010arm study of Japanese patients"],"prefix":"10.1111","volume":"27","author":[{"given":"Yoshihiko","family":"Tomita","sequence":"first","affiliation":[{"name":"Department of Urology, Molecular Oncology Niigata University Graduate School of Medical and Dental Sciences Niigata Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsunori","family":"Tatsugami","sequence":"additional","affiliation":[{"name":"Department of Urology Graduate School of Medical Sciences Kyushu University Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noboru","family":"Nakaigawa","sequence":"additional","affiliation":[{"name":"Department of Urology Yokohama City University Graduate School of Medicine Yokohama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Osawa","sequence":"additional","affiliation":[{"name":"Department of Renal and Genitourinary Surgery Hokkaido University Sapporo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mototsugu","family":"Oya","sequence":"additional","affiliation":[{"name":"Department of Urology Keio University School of Medicine Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroomi","family":"Kanayama","sequence":"additional","affiliation":[{"name":"Department of Urology Graduate School of Biomedical Sciences Tokushima University Tokushima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chihiro","family":"Nakayama Kondoh","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Toranomon Hospital Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Sassa","sequence":"additional","affiliation":[{"name":"Department of Urology Nagoya University Graduate School of Medicine Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Nishimura","sequence":"additional","affiliation":[{"name":"Department of Urology Osaka International Cancer Institute Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Nozawa","sequence":"additional","affiliation":[{"name":"Department of Urology Kindai University Faculty of Medicine Osaka\u2010sayama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Masumori","sequence":"additional","affiliation":[{"name":"Department of Urology Sapporo Medical University School of Medicine Sapporo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhide","family":"Miyoshi","sequence":"additional","affiliation":[{"name":"Department of Urology and Renal Transplantation Yokohama City University Medical Center Yokohama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Kuroda","sequence":"additional","affiliation":[{"name":"Biostatistics Japan Development Center Takeda Pharmaceutical Company Limited Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Tanaka","sequence":"additional","affiliation":[{"name":"PRA Health Sciences Company Limited Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Kimura","sequence":"additional","affiliation":[{"name":"Oncology Clinical Science Oncology Therapeutic Area Unit for Japan and Asia Takeda Pharmaceutical Company Limited Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Tamada","sequence":"additional","affiliation":[{"name":"Department of Urology Osaka City University Graduate School of Medicine Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,8,12]]},"reference":[{"key":"e_1_2_8_2_1","unstructured":"Cancer Information Service.Cancer statistics in Japan \u201918. [Cited 26 Jul 2019]. Available from URL:https:\/\/ganjoho.jp\/en\/professional\/statistics\/brochure\/2018_en.html"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.10.002"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18102195"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.4464"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000074870.54671.98"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-11-0264"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3366"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712126"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816714"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816047"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510016"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30107-3"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.7398"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2018.12.018"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0164-0"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-019-03935-x"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.4158\/EP161259.OR"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-018-3579-7"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2016.1265666"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz056"},{"key":"e_1_2_8_22_1","unstructured":"National Comprehensive Cancer Network.Kidney cancer. NCCN Clinical Practice Guidelines in Oncology. Version: 2.2020.2019. [Cited 30 Apr 2020]. Available from URL:https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/kidney.pdf"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2015.08.002"},{"key":"e_1_2_8_24_1","first-page":"461","article-title":"Good publication practice for communicating company\u2010sponsored medical research: GPP3. Ann. Intern","volume":"163","author":"Battisti WP","year":"2015","journal-title":"Med"}],"container-title":["International Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fiju.14329","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/iju.14329","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/iju.14329","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/iju.14329","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T06:14:36Z","timestamp":1763705676000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/iju.14329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,12]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["10.1111\/iju.14329"],"URL":"https:\/\/doi.org\/10.1111\/iju.14329","archive":["Portico"],"relation":{},"ISSN":["0919-8172","1442-2042"],"issn-type":[{"value":"0919-8172","type":"print"},{"value":"1442-2042","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,12]]},"assertion":[{"value":"2020-02-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}